The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
Dalin Li, Alexander M. Xu, Emebet Mengesha, Rebecca Elyanow, Rachel Gittelman, Heidi Chapman, John C. Prostko, Edwin C. Frias, James L. Stewart, Valeriya Pozdnyakova, Philip Debbas, Angela Mujukian, Arash Horizon, Noah Merin, Sandy Joung, Gregory J. Botwin, Kimia Sobhani, Jane C. Figueiredo, Susan Cheng, Ian M. Kaplan, Dermot McGovern, Akil Merchant, Gil Melmed, Jonathan Braun
Abstract
Lay Summary T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.